Recently, Jiangsu Vicare Pharmaceutical Technology Co., Ltd. (“Jiangsu Vicare”) announced the completion of round B financing of more than 200 million yuan. This round of financing was led by Changjiang Venture Capital, jointly invested by Hongcheng Investment and Huadian Investment, and continued to be supported by Changjiang Industrial Investment and SDIC China Merchants.
The raised funds will be used to accelerate the clinical development of the company’s core innovative drug products and the construction of the CDMO industrialization base.
Jiangsu Vicare Pharmaceutical Technology Co., Ltd. (“Jiangsu Vicare”) was founded in 2010 by professors from China Pharmaceutical University and overseas returnees. It is a high-tech pharmaceutical company focusing on the development of innovative drugs and leading therapies. In 2021, a wholly-owned subsidiary Nanjing Vicare Biomedical Technology Co., Ltd. (“Nanjing Vicare”) will be established to independently operate CRO/CDMO services for the entire drug industry chain. There are more than 400 employees, including 12 doctors and more than 100 masters, and technical personnel account for more than 83%. The company is located in the national-level new area – Biomedicine Valley, Jiangbei New District, Nanjing City. It has invested 200 million yuan to build a high-end drug research and development center covering an area of 20 mu and a construction area of 21,000 square meters.
Based on research and development and guided by industrialization, the company has successively established the Jiangsu Provincial Chemical Innovative Drug Technology Center, the Jiangsu Provincial Enterprise Academician Workstation, the Nanjing Postdoctoral Innovation Practice Base, and the China Pharmaceutical University to jointly build an enterprise graduate student workstation. Up to now, the company has independently developed 11 innovative drugs, 3 of which are in clinical phase I to III, which has formed a gradient development pattern and gradually formed a research and development pipeline focusing on products in the fields of cardiovascular and cerebrovascular, tumor, and endocrine.
The parent company, Jiangsu Vicare, focuses deeply on the development of innovative drugs and leading therapies. It has deployed more than ten innovative drug pipelines, and a number of core products in clinical research have completed key milestones.
Nanjing Vicare is a high-tech pharmaceutical enterprise integrating “chemistry + pharmacy + medicine” one-stop CRO/CDMO service. Mainly engaged in innovative drug and generic drug CMC, clinical and registration (CRO) service innovative drug contract research and development and manufacturing (CDMO) service; production and sales of characteristic raw materials, advanced intermediates and impurities, deepening the construction of a one-stop CRO/CDMO service platform , and built the second-phase CDMO business R&D technology center; acquired the CDMO production base – Hubei Tianshu Pharmaceutical, which is currently under rapid construction and is expected to be put into production in the first quarter of next year.
Nanjing Well provides the whole industry chain and whole life for Novaris, Merck, TEVA, Genmark, Polpharma, Chia Tai Tianqing, Hengrui, CSPC, Qilu, Hansoh, Simcere, Aosaikang, Hisun, Yangzijiang and other biopharmaceutical companies Periodic CRO/CDMO service, has assisted clients to obtain 20 drug registration approvals, 10 clinical approvals, more than 50 registration applications, supplying more than 300 kinds of supporting customized intermediates and raw materials; in 2020, it passed the on-site inspection of the national bureau 4 times.
media reports
Yiou Entrepreneurship TechWeb
This article is transferred from: https://readhub.cn/topic/8m3pP78QeBR
This site is only for collection, and the copyright belongs to the original author.